US Oncology Reports First Quarter 20...(ittee also supported positions that if a...),Health

Date:5/7/2008

ittee also supported positions that, if adopted by FDA, would reduce ESA usage. In particular, ODAC recommended that ESA use not be indicated in patients receiving "potentially curative" treatments or in patients with metastatic breast cancer and/or cancers of the head and neck. The Committee voted against a number of other proposed restrictions and against imposing a restricted distribution system for ESAs. ODAC is an advisory committee of the FDA. While the FDA often follows the recommendations of its advisory committees, it is not required to do so. It is expected that the FDA will consider these and other recommendations and could make additional changes to the ESA label during the second quarter of 2008. In addition, affiliated physicians may already be changing their ESA use as a result of concerns raised by ODAC, and the USON network is active in reviewing evidence and adopting appropriate treatment guidelines. During the first quarter of 2008, $10.2 million of the Company's Adjusted EBITDA was attributable to utilization of ESAs by our network physicians.

Based upon continued uncertainty surrounding ESA utilization, including with respect to physician utilization practices, possible FDA action and other factors, the Company is withdrawing its previously issued EBITDA guidance and is not currently in a position to issue revised guidance for 2008. The Company and US Oncology will broadcast the 2008 first quarter financial results by conference call on Thursday, May 8, 2008 at 10:00 A.M. Central Daylight Time. The archived replay of the event will be available through the news center on the Company's Web site (http://www.usoncology.com).

About US Oncology, Inc.

US Oncology, headquartered in Houston, Texas, supports one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help
'/>"/>

SOURCE US Oncology Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative